A proof-of-concept rat toxicity study highlights the potential utility and challenges of virtual control groups

Area of Science:

• Pharmacology
• Toxicology
• Animal Research Ethics

Background:

• The virtual control group (VCG) concept offers a potential method to decrease animal usage in nonclinical toxicity studies by substituting concurrent control groups (CCGs).
• Investigating the feasibility and reliability of VCGs is crucial for their adoption in drug development.
• Understanding variability in historical control animal data is essential for constructing robust VCGs.

Purpose of the Study:

• To assess the feasibility and reliability of using virtual control groups (VCGs) as replacements for concurrent control groups (CCGs) in nonclinical toxicity studies.
• To identify data curation requirements and key matching criteria for assembling VCGs from historical control databases.
• To evaluate the performance of VCGs against CCGs in a retrospective proof-of-concept study.

Main Methods:

• A historical control database (HCD) from rat toxicity studies was curated to identify trends and variability.
• Key matching criteria such as sex, route of administration, fasting status, and body weight were identified for VCG construction.
• A retrospective proof-of-concept study compared microscopic pathology and clinical pathology endpoints using CCGs and two VCGs derived from the HCD.

Main Results:

• Microscopic pathology assessments and most endpoints showed similar results between VCGs and CCGs.
• The proof-of-concept study identified risks in using VCGs for interpreting subtle test article-related changes, especially in clinical pathology parameters.
• Virtual control groups were found not to be entirely equivalent to concurrent control groups in this specific context.

Conclusions:

• While VCGs show promise for reducing animal use in toxicity studies, they may not be fully equivalent to CCGs, particularly for sensitive clinical pathology endpoints.
• Further research is necessary to determine the broader utility and viability of VCGs in different drug development contexts.
• Careful data curation and consideration of study design parameters are critical for the successful implementation of VCGs.